BMA BIOMEDICALS

Peninsula Laboratories

Rabbit anti Osteogenic Growth Peptide

The Osteogenic Growth Peptide (OGP) is a key factor in the mechanism of the systemic osteogenic response to local bone marrow injury. Its level is increased in the serum in vivo during osteogenic reactions in the form of OGP-OGP binding protein complex. When it is applied to pre-osteoblast in vitro, OGP promotes bone cell proliferation and differentiation, which is indicated by increasing ALP Alkaline phosphatase activity. When it is administered in vivo, OGP stimulates osteogenesis and hematopoiesis.

This antibody was generated by immunization of rabbits with Osteogenic Growth Peptide coupled to a carrier protein.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Catalog Number:	T-4608 (Lot 023340)
Clonality:	Polyclonal
Host species:	Rabbit
Reactivity:	Human
Quantity:	50 µl
Format:	Neat undiluted antiserum, lyophilized, packaged under nitrogen. Reconstitute by adding 50 µl distilled water. This will give the equivalent of undiluted antiserum.
Stability and Storage:	Original vial: 1 year at 4° - 8°C from date of purchase. Stock solution and aliquots thereof: 1 year at -20°C. Avoid freeze-thaw cycles.
Immunogen:	Synthetic peptide H-Ala-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly-OH coupled to carrier protein.
Protein database:	n/a

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst, Switzerland
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch

Applications:

Tested in immunohistochemistry (IHC) and ELISA against Osteogenic Growth Peptide. Other applications like FACS or Western Blot may work as well.
Optimal dilutions should be determined by the end user.

Please see **bma.ch** for protocols and general information.

Approximate working dilution for IHC:
Frozen sections: not tested yet.
Paraffin sections: 1:500; recommended Proteinase K pre-treatment.

Related Products:

T-4605: Rabbit anti (Asp76)-pTH (39-84) (hu), diluted antiserum

This product contains no preservative and is intended for laboratory use and research purposes only. Not for diagnostic or therapeutic applications.

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst, Switzerland
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch